Mak Capital One LLC Buys 9,062,518 Shares of Autolus Therapeutics PLC Sponsored ADR $AUTL

Mak Capital One LLC lifted its stake in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) by 53.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,017,616 shares of the company’s stock after purchasing an additional 9,062,518 shares during the period. Autolus Therapeutics accounts for 6.5% of Mak Capital One LLC’s portfolio, making the stock its 3rd largest position. Mak Capital One LLC owned 9.78% of Autolus Therapeutics worth $42,409,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently bought and sold shares of the stock. Marex Group plc acquired a new position in shares of Autolus Therapeutics during the second quarter valued at $28,000. R Squared Ltd increased its position in Autolus Therapeutics by 40.1% in the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after purchasing an additional 8,730 shares during the period. Invesco Ltd. raised its holdings in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Autolus Therapeutics by 41.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock worth $88,000 after purchasing an additional 11,289 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in Autolus Therapeutics by 580.8% during the 3rd quarter. Squarepoint Ops LLC now owns 91,957 shares of the company’s stock valued at $150,000 after purchasing an additional 78,450 shares during the period. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Performance

AUTL opened at $1.51 on Tuesday. The firm’s fifty day moving average is $1.54 and its two-hundred day moving average is $1.53. The firm has a market cap of $401.87 million, a PE ratio of -1.82 and a beta of 1.95. Autolus Therapeutics PLC Sponsored ADR has a twelve month low of $1.11 and a twelve month high of $2.70.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on AUTL shares. HC Wainwright began coverage on shares of Autolus Therapeutics in a research report on Tuesday, February 17th. They set a “buy” rating and a $9.00 price target for the company. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, January 21st. Finally, Needham & Company LLC reduced their price target on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, January 12th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.